Teriparatide

[MAF] Teriparatide biosimilar (Sondelbay) Injection, Prefilled Pen 600 mcg/2.4 mL

1. For treatment of patients with severe established osteoporosis (T-score ≤ -3.

2. with a history of ≥ 2 vertebral fractures or ≥ 2 fragility fractures. The maximum lifetime duration of teriparatide treatment should be limited to 24 months.

View legend

04/06/2025 Romosozumab and teriparatide for treating osteoporosis

[NR] The Ministry of Health’s Drug Advisory Committee has not recommended:

• Romosozumab or teriparatide reference biologic (Forteo) for inclusion on the MOH List of Subsidised Drugs for treating postmenopausal women with osteoporosis who are at high risk for fracture; and

• Teriparatide reference biologic (Forteo) for inclusion on the MOH List of Subsidised Drugs for treating men with primary or hypogonadal osteoporosis who are at high risk for fracture, or patients with glucocorticoid-induced osteoporosis who are at high risk for fracture

due to uncertain extent of clinical benefit and unfavourable cost-effectiveness compared with subsidised alternatives.

04/06/2025 Teriparatide biosimilar for treating osteoporosis

The Ministry of Health’s Drug Advisory Committee has recommended teriparatide biosimilar (Sondelbay) 600 mcg/2.4 mL injection for treatment of patients with severe established osteoporosis (T-score ≤ -3.0) with a history of ≥ 2 vertebral fractures or ≥ 2 fragility fractures. The maximum lifetime duration of teriparatide treatment should be limited to 24 months. The decision was based on the acceptable pricing proposal from the company.

Funding status

[R] Teriparatide biosimilar (Sondelbay) 600 mcg/2.4 mL injection is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 August 2025.

[NR] MAF assistance does not apply to other brand(s), formulation(s) or strengths(s) of teriparatide for treating osteoporosis.

View legend

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration